[{"path":"/safety/recalls-market-withdrawals-safety-alerts/bayer-statement-voluntary-recall-two-lots-kogenater-fs-antihemophilic-factor-recombinant-united","field_change_date_2":"07/19/2019","field_brand_name":"<a href=\"/safety/recalls-market-withdrawals-safety-alerts/bayer-statement-voluntary-recall-two-lots-kogenater-fs-antihemophilic-factor-recombinant-united\">Kogenate®</a>","field_product_description":"Kogenate® FS antihemophilic factor (recombinant) ","field_recall_reason_description":"Mislabeling-contains the FVIII hemophilia A treatment, Jivi® antihemophilic factor ","field_recall_reason":"Mislabeling","field_company_name":"Bayer","field_product_type":"","term_node_tid":"Prescription Drugs","field_regulated_product_field":"Biologics","all-terms-rewrite":"Biologics, Prescription Drugs","publicationDate":"2019-07-19T04:00:00.000Z","link":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bayer-statement-voluntary-recall-two-lots-kogenater-fs-antihemophilic-factor-recombinant-united","canonicalId":"d0153b87f16b2fe8688399669a87832226dd8c3a7fc3485e444494fd165e06ae","title":"Bayer Statement on Voluntary Recall of Two Lots of Kogenate® FS Antihemophilic Factor (Recombinant) in the United States","description":"Bayer is voluntarily recalling two lots of Kogenate® FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemophilia","feedName":"fda","feedSource":"fda","categories":[]}]